Company profile: Araris Biotech
1.1 - Company Overview
Company description
- Provider of proprietary peptide linker technology for efficient payload attachment without antibody engineering, enabling creation of stable, homogenous, highly soluble antibody-drug conjugates (ADCs) with improved therapeutic efficacy and reduced side effects; also offers ADC development using off-the-shelf antibodies to deliver drugs to cancer cells with improved stability and solubility in a cost-effective manner.
Products and services
- ADC Development: Off-the-shelf antibody approach engineers ADCs that deliver drugs to cancer cells with improved stability and solubility, using the linker to produce homogenous constructs without antibody reengineering
- ADC Platform: Proprietary platform architects stable, homogenous antibody-drug conjugates with improved therapeutic efficacy and reduced side effects by refining payload attachment chemistry for high solubility
- Araris Linker Technology: Peptide-based linker system enables efficient payload attachment without antibody engineering, creating homogenous, stable, highly soluble ADCs in a cost-effective manner with improved therapeutic efficacy and reduced side effects
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Araris Biotech
Sprint Bioscience
HQ: Sweden
Website
- Description: Provider of a fragment-based, modular gene-to-lead drug discovery platform covering protein expression/purification, fragment screening, X-ray crystallography, and fragment-to-lead expansion. Develops small-molecule candidates from idea to preclinical stage for licensing. Programs: TREX1 (DISA), VRK1 (VADA, licensed to Day One Biopharmaceuticals), NNMT (NIMA). Based in Stockholm, Sweden.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sprint Bioscience company profile →
Breath Therapeutics
HQ: Germany
Website
- Description: Provider of inhaled investigational therapies for rare respiratory diseases, combining novel formulations of existing drugs with cutting-edge inhalation technology. Pipeline includes Liposomal Cyclosporine A for Inhalation for bronchiolitis obliterans syndrome to deliver drug to lungs while minimizing systemic exposure, and inhaled colistimethate sodium for non-cystic fibrosis bronchiectasis targeting Pseudomonas aeruginosa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Breath Therapeutics company profile →
PathogenDx
HQ: United States
Website
- Description: Provider of RT-PCR and DNA microarray-based pathogen detection solutions, including assays for SARS-CoV-2 genes and variants (DetectX-Rv, DetectX-Cv), environmental SARS-CoV-2 screening (EnviroX-Rv), a UTI panel detecting 26 pathogens and 12 antibiotic resistance markers (D3 Array-UTI), and semi-quantitative fungal and bacterial assays (QuantX Fungal, QuantX Bacterial).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PathogenDx company profile →
Sloning Biotechnology
HQ: Germany
Website
- Description: Provider of tailored protein engineering solutions for industrial and biopharmaceutical sectors, leveraging the patented Slonomics technology platform to build DNA molecules with exceptional features regarding sequence limitations, reliability, and production cost on an industrial-scale robotic system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sloning Biotechnology company profile →
Clean Cells
HQ: France
Website
- Description: Provider of biosafety and quality control testing for biopharmaceuticals, including vaccines, monoclonal antibodies, and cell and gene therapies; GMP manufacturing of cell and virus banks and Master/Working Cell Banks; secure GMP and non-GMP storage; development of cytotoxicity potency assays; purity and identity testing; and production of experimental drugs such as cell therapy products and therapeutic phages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clean Cells company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Araris Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Araris Biotech
2.2 - Growth funds investing in similar companies to Araris Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Araris Biotech
4.2 - Public trading comparable groups for Araris Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →